• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

William (Bill) Barry, PhD


  • Faul LA, Luta G, Sheppard V, Isaacs C, Cohen HJ, Muss HB, Yung R, Clapp JD, Winer E, Hudis C, Tallarico M, Wang J, Barry WT, Mandelblatt JS.Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901.J Cancer Surviv. 2014 Jun 11.
  • Stevenson M, Christensen J, Shoemaker D, Foster T, Barry WT, Tong BC, Wahidi M, Shofer S, Datto M, Ginsburg G, Crawford J, D'Amico T, Ready N.Tumor acquisition for biomarker research in lung cancer.Cancer Invest. 2014 Jul;32(6):291-8.
  • Barry WT, Perou CM, Marcom PK, Carey LA, Ibrahim JG.The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.J Biopharm Stat. 2014 May 16.
  • Freedman RA, Vaz-Luis I, Barry WT, Lii H, Lin NU, Winer EP, Keating NL.Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy.Breast Cancer Res Treat. 2014 Jun(2):491-501.
  • Mandelblatt JS, Makgoeng SB, Luta G, Hurria A, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher B, Winer EP, Hudis C, Cohen HJ, Muss HB.A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901.Journal Of Geriatric Oncology. 2013 Oct;4(4):353-61.
  • Liu JF, Kindelberger D, Doyle C, Lowe A, Barry WT, Matulonis UA.Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients.Gynecol Oncol. 2013 Aug 13.
  • Jones LW, Fels DR, West M, Allen JD, Broadwater G, Barry WT, Wilke LG, Masko E, Douglas PS, Dash RC, Povsic TJ, Peppercorn J, Marcom PK, Blackwell KL, Kimmick G, Turkington TG, Dewhirst MW.Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy.Cancer Prev Res (Phila Pa). 2013 Sep;6(9):925-37.
  • Brown JQ, Bydlon TM, Kennedy SA, Caldwell ML, Gallagher JE, Junker M, Wilke LG, Barry WT, Geradts J, Ramanujam N.Optical spectral surveillance of breast tissue landscapes for detection of residual disease in breast tumor margins.PLoS ONE. 2013;8(7):e69906.
  • Zhou YH, Barry WT, Wright FA.Empirical pathway analysis, without permutation.Biostatistics. 2013 Jul;14(3):573-85.
  • Mandelblatt JS, Faul LA, Luta G, Makgoeng SB, Isaacs C, Taylor K, Sheppard VB, Tallarico M, Barry WT, Cohen HJ.Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901.J Clin Oncol. 2012 Jul 20;30(21):2609-14.
  • Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF, Wulfkuhle J, Liotta LA, Lem S, Baker JC, Ford AC, Wilke LG, Zalles C, Kuderer NM, Hoffman AW, Shivraj M, Mehta P, Williams J, Tolbert N, Lee LW, Pilie PG, Yu D, Seewaldt VL.Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways.Breast Cancer Res Treat. 2012 Apr;132(2):487-98.
  • Owzar K, Barry WT, Jung SH.Statistical considerations for analysis of microarray experiments.Clin Transl Sci. 2011 Dec;4(6):466-77. Review.
  • Gatti DM, Barry WT, Nobel AB, Rusyn I, Wright FA.Heading down the wrong pathway: on the influence of correlation within gene sets.BMC Genomics. 2010;11:574.
  • Geradts J, Bean SM, Bentley RC, Barry WT.The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features.Cancer Invest. 2010 Nov;28(9):969-77.
  • Barry WT, Kernagis DN, Dressman HK, Griffis RJ, Hunter JD, Olson JA, Marks JR, Ginsburg GS, Marcom PK, Nevins JR, Geradts J, Datto MB.Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome.J Clin Oncol. 2010 May 1;28(13):2198-206.